Nuclear endpoint of Wnt signaling: neoplastic transformation induced by transactivating lymphoid-enhancing factor 1
- PMID: 9874785
- PMCID: PMC15106
- DOI: 10.1073/pnas.96.1.139
Nuclear endpoint of Wnt signaling: neoplastic transformation induced by transactivating lymphoid-enhancing factor 1
Abstract
The interaction between beta-catenin and LEF-1/TCF transcription factors plays a pivotal role in the Wnt-1 signaling pathway. The level of beta-catenin is regulated by partner proteins, including glycogen synthase kinase-3beta (GSK-3beta) and the adenomatous polyposis coli (APC) tumor suppressor protein. Genetic defects in APC are responsible for a heritable predisposition to colon cancer. APC protein and GSK-3beta bind beta-catenin, retain it in the cytoplasm, and facilitate the proteolytic degradation of beta-catenin. Abrogation of this negative regulation allows beta-catenin to translocate to the nucleus and to form a transcriptional activator complex with the DNA-binding protein lymphoid-enhancing factor 1 (LEF-1). This complex is thought to be involved in tumorigenesis. Here we show that covalent linkage of LEF-1 to beta-catenin and to transcriptional activation domains derived from the estrogen receptor or the herpes simplex virus protein VP16 generates transcriptional regulators that induce oncogenic transformation of chicken embryo fibroblasts. The chimeras between LEF-1 and beta-catenin or VP16 are constitutively active, whereas fusions of LEF-1 to the estrogen receptor are regulatable by estrogen. These experiments document the oncogenicity of transactivating LEF-1 and show that the transactivation domain normally provided by beta-catenin can be replaced by heterologous activation domains. These results suggest that the transactivating function of the LEF-1/beta-catenin complex is critical for tumorigenesis and that this complex transforms cells by activating specific LEF-1 target genes.
Figures





Similar articles
-
Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression.Mol Cell Biol. 1999 Aug;19(8):5696-706. doi: 10.1128/MCB.19.8.5696. Mol Cell Biol. 1999. PMID: 10409758 Free PMC article.
-
E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation.J Cell Sci. 1999 Apr;112 ( Pt 8):1237-45. doi: 10.1242/jcs.112.8.1237. J Cell Sci. 1999. PMID: 10085258
-
Signaling through beta-catenin and Lef/Tcf.Cell Mol Life Sci. 1999 Oct 30;56(5-6):523-37. doi: 10.1007/s000180050449. Cell Mol Life Sci. 1999. PMID: 11212302 Free PMC article. Review.
-
Regulation of lymphoid enhancer factor 1/T-cell factor by mitogen-activated protein kinase-related Nemo-like kinase-dependent phosphorylation in Wnt/beta-catenin signaling.Mol Cell Biol. 2003 Feb;23(4):1379-89. doi: 10.1128/MCB.23.4.1379-1389.2003. Mol Cell Biol. 2003. PMID: 12556497 Free PMC article.
-
TCF: Lady Justice casting the final verdict on the outcome of Wnt signalling.Biol Chem. 2002 Feb;383(2):255-61. doi: 10.1515/BC.2002.027. Biol Chem. 2002. PMID: 11934263 Review.
Cited by
-
Discovering small molecules as Wnt inhibitors that promote heart regeneration and injury repair.J Mol Cell Biol. 2020 Jan 22;12(1):42-54. doi: 10.1093/jmcb/mjz023. J Mol Cell Biol. 2020. PMID: 30925593 Free PMC article.
-
Beta-catenin and epithelial tumors: a study based on 374 oropharyngeal cancers.Biomed Res Int. 2014;2014:948264. doi: 10.1155/2014/948264. Epub 2014 Jan 8. Biomed Res Int. 2014. PMID: 24511551 Free PMC article.
-
Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression.Mol Cell Biol. 1999 Aug;19(8):5696-706. doi: 10.1128/MCB.19.8.5696. Mol Cell Biol. 1999. PMID: 10409758 Free PMC article.
-
Modeling Wnt signaling by CRISPR-Cas9 genome editing recapitulates neoplasia in human Barrett epithelial organoids.Cancer Lett. 2018 Nov 1;436:109-118. doi: 10.1016/j.canlet.2018.08.017. Epub 2018 Aug 23. Cancer Lett. 2018. PMID: 30144514 Free PMC article.
-
Modular Cre/lox system and genetic therapeutics for colorectal cancer.J Biomed Biotechnol. 2009;2009:358230. doi: 10.1155/2009/358230. Epub 2009 Sep 30. J Biomed Biotechnol. 2009. PMID: 19809520 Free PMC article. Review.
References
-
- Cadigan K M, Nusse R. Genes Dev. 1997;11:3286–3305. - PubMed
-
- Morin P J, Sparks A B, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler K W. Science. 1997;275:1787–1790. - PubMed
-
- Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Science. 1997;275:1790–1792. - PubMed
-
- Nusse R, Varmus H E. Cell. 1982;31:99–109. - PubMed
-
- Nusse R, van Ooyen A, Cox D, Fung Y K, Varmus H. Nature (London) 1984;307:131–136. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous